Stay updated with breaking news from Prince Pipe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nominal Index [Citation 1 – 175]Rohit Dembiwal v. Tata Consultancy Services Ltd. & Ors 2024 LiveLaw (Bom) 1Mirza Himayat Baig v. State of Maharashtra 2024 LiveLaw (Bom) 2M/s. Hindustan Level Employees...
The view is that largecap pharma names like Lupin, DRL, Aurobindo, and Sun Pharma may continue to perform well this quarter. The US pharma companies and distributors have a positive outlook, despite price erosion. Sun Pharma's Taro business reported a healthy performance. The US market looks promising for these companies. As a house, we are focusing more on larger caps than midcaps in the current scenario.
(This story has not been edited by THE WEEK and is auto-generated from a PTI
Prince Pipes: JM Financial has tweaked its FY24-25 estimates and suggested a target of Rs 730. It continued to maintain a positive view on the Prince Pipes stock as it is well placed to ride on real estate recovery and product diversification.
The company logged a 7 percent year-on-year rise in net profit at Rs 94.11 crore for the quarter ended March.